AIM
SCNI

ARK Investment Management’s Scinai Immunotherapeutics SCNI Stock Holding History

ARK Investment Management’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-98
Closed -$37K – 296
2021
Q1 		$37K Sell
98
-318
-76% -$139K ﹤0.01% 285
2020
Q4 		$117K Buy
416
+217
+109% +$263K ﹤0.01% 240
2020
Q3 		$776K Buy
+199
New +$764K ﹤0.01% 168

Other funds holding SCNI

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TPWA
TRUE Private Wealth Advisors Salem, Oregon $1.16B AUM 36.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

ARK Investment Management's SCNI Position: Q2 2021 in Review

ARK Investment Management sold out of Scinai Immunotherapeutics (SCNI) in Q2 2021, closing a stake of 98 shares — an estimated $37K sold.

ARK Investment Management first reported a position in SCNI in Q3 2020 and held it in 3 quarters. The position peaked at $776K in Q3 2020. 16 funds tracked by Wall St. Rank hold SCNI as of Q2 2021.

  • ARK Investment Management reported no remaining Scinai Immunotherapeutics position as of Q2 2021 after selling out during the quarter.
  • ARK Investment Management sold 98 Scinai Immunotherapeutics shares in Q2 2021, an estimated $37K.
  • ARK Investment Management first reported a position in Scinai Immunotherapeutics in Q3 2020 and held it in 3 quarters.
  • ARK Investment Management's Scinai Immunotherapeutics position peaked at $776K in Q3 2020.
  • 16 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2021.

Based on ARK Investment Management's 13F filing for Q2 2021, filed 5 Aug 2021.